Due Diligence on incredible undervalued Psilocybin Stock that is very similar to $CMPS
$CMPS
AI SUMMARY โ Post discusses an undervalued psilocybin stock compared to CMPS (Compass Pathways). Key risks include regulatory uncertainty around psychedelic drug approval, early-stage company execution risk, and market sentiment volatility in this emerging sector.
| TICKER | CMPS |
USER | u/pwirk794 |
| RATING |
BULLISH |
ENTRY |
$14.12
|
| POSITION |
710 sh
SYN
|
BOOK VAL |
$10028.41 |
| CURRENT |
$14.08 |
P&L % |
-0.28%
|
| CURR VAL |
$10000.00 |
P&L $ |
-28.41
|